|
| |
Access PharmaceuticalsAccess Pharmaceuticals is an emerging biotechnology company focused on the development and commercialization of products using the companies targeted delivery systems to improve clinical outcomes for patients. Together with our subsidiaries we have proprietary patents or rights to a number of drug delivery platforms,Synthetic polymer targeted delivery,Vitamin mediated targeted delivery, Vitamin mediated oral delivery, Bioerodible cross-linker technology, and Hydrogel particle aggregate chnology. The company’s primary development focus is in the area of oncology with its polymer therapeutics program. The company’s lead product, AP5346, is in Phase II clinical development and is a polymer of DACH-platinum, the active principal of oxaliplatin (Eloxatin; sanofiventis).
| Contact Details: |
| 2600 N. Stemmons Freeway Suite 176 |
| Dallas |
| |
| 75207-2107 |
| United States of America |
| Tel: | 214 905 5100 |
| Fax: | 214 905 5101 |
| Email: | akc@accesspharma.com |
| WWW: | www.accesspharma.com/
|
| |
Recent Publications by Access Pharmaceuticals: |  |
ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic.
ProLindac (AP5346) is DACH (diaminocyclohexane) platinum polymer prodrug... | 13th August, 2009
| Access Pharmaceuticals, Inc., 2600 Stemmons Freeway, Suite 176, Dallas, TX
| Adv Drug Deliv Rev. 2009 Nov 12;61(13):1214-9. Epub 2009 Aug 9.
DOI Direct Link |
Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent.
Syntheses of the novel polymer-bound platinum-based chemotherapeutic agent... | 16th May, 2007
| Access Pharmaceuticals, Inc., 2600 Stemmons Freeway, Suite 176, Dallas,
| Bioconjug Chem. 2006 Sep-Oct;17(5):1270-9.
DOI Direct Link |
Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
PURPOSE: AP5346 is designed to target a diaminocyclohexane platinum (Pt)... | 19th July, 2006
| Access Pharmaceuticals, Inc., Dallas, Texas, USA.
| Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2248-54.
DOI Direct Link |
Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours.
Targeted chemotherapy for cancer treatment offers a great potential... | 22nd December, 2004
| Access Pharmaceuticals Australia Pty Ltd., Targeted Delivery, Unit 5,
| J Inorg Biochem. 2004 Oct;98(10):1625-33.
DOI Direct Link |
Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium.
Despite early successes in oral drug delivery of small molecules such as... | 16th December, 2004
| Access Pharmaceuticals Australia Pty Ltd, Unit 5 Gibbes St. 2067 NSW
| J Drug Target. 2004 Feb;12(2):113-23.
DOI Direct Link |
→View more Access Pharmaceuticals research publications. |
Press Releases on Access Pharmaceuticals:
|
 |
| ChangeWave Issues Buy Recommendation on Access Pharmaceuticals |
17th November, 2009 |
Access Pharmaceuticals, Inc. |
DALLAS, Nov. 17 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) today announced that a recommendation report was issued by ChangeWave, a research network that
|
| Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America |
11th November, 2009 |
Access Pharmaceuticals, Inc. |
-- Co-Promotion: Access continues to seek potential co-promotion
arrangements with pharmaceutical and biotechnology companies in the
oncology and oncology supportive care fields.
|
| Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) |
6th October, 2009 |
Access Pharmaceuticals, Inc. |
DALLAS, Oct. 6 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that it had signed an agreement with iMedicor (OTC Bulletin Board: VMCI) for the North
|
| New Report Just Published: World Multiple Myeloma Therapeutics Market Report |
7th July, 2009 |
Reportlinker |
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Multiple Myeloma Therapeutics Market
http://www.reportlinker.com/p0119496/World
|
| Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis |
7th July, 2009 |
Access Pharmaceuticals, Inc. |
DALLAS, July 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today new preclinical data demonstrating that thiarabine shows remarkable efficacy in the
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 742 times since April 2007, the link to the organisation's website has been followed 107 times Recent Search Terms used to find this page: vitamin mediated drug delivery systems | Vitamin-mediated drug delivery | vitamin-mediated targeting as a potential mechanism | . Search for more companies in Dallas Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Access Pharmaceuticals |
